Abstract
Progress in the field of NK cell receptors (NKRs) and their ligands has revolutionized our concept of how NK cells selectively recognize and lyse tumor while sparing normal cells. Major families of NKRs that inhibit and activate NK cells to lyse target cells have been characterized, including killer cell immunoglobulin-like receptors (KIRs), C-type lectins, and natural cytotoxicity receptors. Identification of NK receptor ligands such as HLA, MHC class I chain-related genes A and B – MICA/B, etc. further clarifies the role of NKR/ligand interactions in NK cell function. Given the extensive genomic diversity of KIRs, HLA and MIC, it is reasonable to imagine that genotypes encoding imbalanced inhibitory and activating interactions may contribute to susceptibility or resistance to human diseases, including cancers. This review will discuss two cell-surface receptor/ligand systems involved in NK cell recognition of tumor targets – KIR/HLA and NKG2D/MIC and the potential relevance of their genetic polymorphism in malignancies.
Keywords: NK cell receptors, NK receptor ligands, polymorphism, malignancies
Current Cancer Therapy Reviews
Title: NK Cell Receptor and MHC Gene Polymorphisms, Potential Relevance in Malignancies
Volume: 4 Issue: 2
Author(s): Anastassia Mihaylova, Snejina Mihailova and Elissaveta Naumova
Affiliation:
Keywords: NK cell receptors, NK receptor ligands, polymorphism, malignancies
Abstract: Progress in the field of NK cell receptors (NKRs) and their ligands has revolutionized our concept of how NK cells selectively recognize and lyse tumor while sparing normal cells. Major families of NKRs that inhibit and activate NK cells to lyse target cells have been characterized, including killer cell immunoglobulin-like receptors (KIRs), C-type lectins, and natural cytotoxicity receptors. Identification of NK receptor ligands such as HLA, MHC class I chain-related genes A and B – MICA/B, etc. further clarifies the role of NKR/ligand interactions in NK cell function. Given the extensive genomic diversity of KIRs, HLA and MIC, it is reasonable to imagine that genotypes encoding imbalanced inhibitory and activating interactions may contribute to susceptibility or resistance to human diseases, including cancers. This review will discuss two cell-surface receptor/ligand systems involved in NK cell recognition of tumor targets – KIR/HLA and NKG2D/MIC and the potential relevance of their genetic polymorphism in malignancies.
Export Options
About this article
Cite this article as:
Mihaylova Anastassia, Mihailova Snejina and Naumova Elissaveta, NK Cell Receptor and MHC Gene Polymorphisms, Potential Relevance in Malignancies, Current Cancer Therapy Reviews 2008; 4 (2) . https://dx.doi.org/10.2174/157339408784310070
DOI https://dx.doi.org/10.2174/157339408784310070 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Potential of Nanocarriers in Genetic Immunization
Recent Patents on Drug Delivery & Formulation Exosomes: Natural Carriers for siRNA Delivery
Current Pharmaceutical Design Pharmaceutical and Biomedical Potential of PEGylated Dendrimers
Current Pharmaceutical Design Evaluation of Non-Coding RNAs as Potential Targets in Head and Neck Squamous Cell Carcinoma Cancer Stem Cells
Current Drug Targets Potassium Channels are a New Target Field in Anticancer Drug Design
Recent Patents on Anti-Cancer Drug Discovery Restoration of Chemoresistance Mechanism by Novel Drug Therapies in Breast Cancer Cell Lines
Current Drug Therapy Curcumin: Not So Spicy After All
Mini-Reviews in Medicinal Chemistry Characterization of the Lymphotropic Amplicons-6 and Tamplicon-7 Vectors Derived from HHV-6 and HHV-7
Current Gene Therapy The Chemical Structure and Bioactivity of Cycloartane-type Compounds
Current Organic Chemistry Chemokine Receptors as Targets for Cancer Therapy
Current Pharmaceutical Design An Expanding Appreciation of the Role Chemokine Receptors Play in Cancer Progression
Current Pharmaceutical Design Chemistry and Pharmacological Properties of Some Natural and Synthetic Antioxidants for Heavy Metal Toxicity
Current Medicinal Chemistry Impact of Curcumin on Microsomal Enzyme Activities: Drug Interaction and Chemopreventive Studies
Current Medicinal Chemistry Cancer-Associated Carbonic Anhydrases and Their Inhibition
Current Pharmaceutical Design Current and Potential Treatments for Cervical Cancer
Current Cancer Drug Targets Emerging Therapies in Relapsing-Remitting Multiple Sclerosis
Reviews on Recent Clinical Trials Matrix Metalloproteinase Inhibitors: New Challenges in the Era of Post Broad-Spectrum Inhibitors
Current Pharmaceutical Design Gamma Secretase Inhibitor: Therapeutic Target via NOTCH Signaling in T Cell Acute Lymphoblastic Leukemia
Current Drug Targets Anticancer Agent Ukrain and Bortezomib Combination is Synergistic in 4T1 Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Targeting the Cancer-Stroma Interaction: A Potential Approach for Pancreatic Cancer Treatment
Current Pharmaceutical Design